Research Paper Volume 8, Issue 12 pp 3520—3534
Delivery of sFIT-1 engineered MSCs in combination with a continuous low-dose doxorubicin treatment prevents growth of liver cancer
Figure 1. The content of sFlt1 in supernatant increased significantly in MSCs-sFlt1 group as compared with day-matched MSCs-adv group or MSCs group. Data from 3 independent experiments are shown. *P<0.05 versus MSC-sFlt1 group.